Literature DB >> 3499316

Emergence of resistance in gram-negative bacteria during therapy with expanded-spectrum cephalosporins.

D L Dworzack1, M P Pugsley, C C Sanders, E A Horowitz.   

Abstract

To assess the clinical importance of emergence of beta-lactam resistance caused by stable derepression of chromosomal beta-lactamases, sequential cultures from patients treated with expanded-spectrum cephalosporins were monitored for the persistence of bacteria possessing these enzymes. Antibiotic susceptibilities and beta-lactamase production before and after cefoxitin induction were determined in sequential isolates of individual bacterial strains. Of 49 strains isolated from 44 patients, 25 strains (51%) were eradicated by cephalosporin therapy, 17 strains (35%) persisted with unchanged susceptibility in sequential cultures, and 7 strains (14%) from 7 patients developed multiple beta-lactam resistance during cephalosporin therapy. In 6 of the 7 strains, resistance was associated with stable derepression of beta-lactamases. In the patient group whose strains developed resistance, subsequent use of non-beta-lactam antibiotics was more frequent and mortality was higher.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3499316     DOI: 10.1007/BF02013110

Source DB:  PubMed          Journal:  Eur J Clin Microbiol        ISSN: 0722-2211            Impact factor:   3.267


  17 in total

1.  Evidence for multiple forms of type I chromosomal beta-lactamase in Pseudomonas aeruginosa.

Authors:  M L Gates; C C Sanders; R V Goering; W E Sanders
Journal:  Antimicrob Agents Chemother       Date:  1986-09       Impact factor: 5.191

2.  Susceptibility of Enterobacter to cefamandole: evidence for a high mutation rate to resistance.

Authors:  C M Findell; J C Sherris
Journal:  Antimicrob Agents Chemother       Date:  1976-06       Impact factor: 5.191

3.  Cefamandole nafate therapy of respiratory tract, skin, and soft tissue infections in 74 patients.

Authors:  R L Perkins; R J Fass; J F Warner; R B Prior; T M File; R R Tight; W G Gardner; D E Ruiz; T G Slama
Journal:  J Infect Dis       Date:  1978-05       Impact factor: 5.226

4.  Resistance to cefamandole: derepression of beta-lactamases by cefoxitin and mutation in Enterobacter cloacae.

Authors:  T D Gootz; C C Sanders; R V Goering
Journal:  J Infect Dis       Date:  1982-07       Impact factor: 5.226

5.  Comparative analysis of conjugative plasmids mediating gentamicin resistance in Staphylococcus aureus.

Authors:  R V Goering; E A Ruff
Journal:  Antimicrob Agents Chemother       Date:  1983-09       Impact factor: 5.191

6.  [Enterobacter cloacae. In vivo emergence of a variant resistant to new beta-lactams during treatment with lamoxactam-gentamicin].

Authors:  V Jarlier; A Philippon; M H Nicolas; R Bismuth; G Paul; J Fusciardi
Journal:  Pathol Biol (Paris)       Date:  1984-05

7.  Insensitivity of peptidoglycan biosynthetic reactions to beta-lactam antibiotics in a clinical isolate of Pseudomonas aeruginosa.

Authors:  D Mirelman; Y Nuchamowitz; E Rubinstein
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

8.  Emergence of resistance to beta-lactam and aminoglycoside antibiotics during moxalactam therapy of Pseudomonas aeruginosa infections.

Authors:  L C Preheim; R G Penn; C C Sanders; R V Goering; D K Giger
Journal:  Antimicrob Agents Chemother       Date:  1982-12       Impact factor: 5.191

9.  beta-Lactam-resistant Pseudomonas aeruginosa with modified penicillin-binding proteins emerging during cystic fibrosis treatment.

Authors:  A J Godfrey; L E Bryan; H R Rabin
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

10.  Moxalactam therapy for bacterial infections.

Authors:  D J Winston; R W Busuttil; T O Kurtz; L S Young
Journal:  Arch Intern Med       Date:  1981-11
View more
  14 in total

1.  Review of the pharmacology, pharmacokinetics, and clinical use of cephalosporins.

Authors:  D Kalman; S L Barriere
Journal:  Tex Heart Inst J       Date:  1990

Review 2.  Resistance to third generation cephalosporins: the current situation.

Authors:  J C Pechère
Journal:  Infection       Date:  1989 Sep-Oct       Impact factor: 3.553

3.  Differences in the resistant variants of Enterobacter cloacae selected by extended-spectrum cephalosporins.

Authors:  J C Fung-Tomc; E Gradelski; E Huczko; T J Dougherty; R E Kessler; D P Bonner
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

4.  Bacteraemia caused by Escherichia coli and by Enterobacteriaceae producing inducible chromosomal beta-lactamases.

Authors:  P Søgaard; P Tauris
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-03       Impact factor: 3.267

5.  Susceptibility of stably derepressed beta-lactamase producing strains to imipenem and four quinolones.

Authors:  R N Jones; A L Barry
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-02       Impact factor: 3.267

Review 6.  Clinical importance of inducible beta-lactamases in gram-negative bacteria.

Authors:  C C Sanders; W E Sanders
Journal:  Eur J Clin Microbiol       Date:  1987-08       Impact factor: 3.267

7.  In vitro evaluation of BRL 42715, a novel beta-lactamase inhibitor.

Authors:  K Coleman; D R Griffin; J W Page; P A Upshon
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

8.  Septicaemia caused by an Enterobacter cloacae strain varying in resistance against cephalosporins.

Authors:  B M Andersen; I M Dahl; R C George; A Gilfillian
Journal:  Infection       Date:  1989 May-Jun       Impact factor: 3.553

Review 9.  Beta-lactamases: current situation and clinical importance.

Authors:  J Garau
Journal:  Intensive Care Med       Date:  1994-07       Impact factor: 17.440

10.  Epidemiological risk factors for isolation of ceftriaxone-resistant versus -susceptible citrobacter freundii in hospitalized patients.

Authors:  Peter W Kim; Anthony D Harris; Mary-Claire Roghmann; J Glenn Morris; Arjun Strinivasan; Eli N Perencevich
Journal:  Antimicrob Agents Chemother       Date:  2003-09       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.